Healthcare & Life Sciences

Akribion Therapeutics

Germany
Sign in to unlock

About

Akribion Therapeutics develops an RNA-guided, nuclease-based platform technology for programmable cell depletion by using its G-dase® E payload to selectively kill target cells through DNA and RNA shredding, initially focusing on HPV-induced oropharyngeal head and neck cancer and exploring uses in oncology, autoimmune, fibrosis, and infectious diseases.

Explore Akribion Therapeutics's full profile on Brouky

Funding rounds, investor list, and risk signals — unlock with a subscription.

Sign in to unlockView pricing